Literature DB >> 16958000

Leptin in the field of hepatic fibrosis: a pivotal or an incidental player?

Sotirios K Bethanis1, Stamatios E Theocharis.   

Abstract

Leptin is a 16-kDa nonglycosylated protein primarily secreted from the adipocytes of white fat; minor levels of regulated leptin expression also occurs at other sites such as placenta, skeletal muscle, the stomach fundus, and culture-activated hepatic stellate cells (HSCs). Leptin is primarily involved in the regulation of food intake and body composition through a central feedback mechanism linking food ingestion, hypothalamus, and adipose tissue mass. In recent years, however, emerging evidence has suggested a critical role of leptin in hepatic inflammation and fibrogenesis and the influence of leptin on chronic liver disease has been an area of active research worldwide. In this review the data on the in vivo and in vitro actions of leptin on liver cells in experimental animal models of liver injury and the effects of leptin on human liver are discussed, with a focus on three distinct fields of chronic liver diseases: nonalcoholic steatohepatitis, alcoholic liver disease, chronic viral hepatitis, and, especially, hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16958000     DOI: 10.1007/s10620-006-9126-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  98 in total

Review 1.  Obesity and the regulation of energy balance.

Authors:  B M Spiegelman; J S Flier
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

2.  Leptin and liver fibrosis: a matter of fat.

Authors:  Fabio Marra
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

3.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

Review 4.  Cytokines and cellular crosstalk involved in the activation of fat-storing cells.

Authors:  A M Gressner
Journal:  J Hepatol       Date:  1995       Impact factor: 25.083

5.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

6.  Leptin deficiency enhances sensitivity to endotoxin-induced lethality.

Authors:  R Faggioni; G Fantuzzi; C Gabay; A Moser; C A Dinarello; K R Feingold; C Grunfeld
Journal:  Am J Physiol       Date:  1999-01

Review 7.  Histopathologic findings in chronic hepatitis C.

Authors:  H P Fischer; E Willsch; E Bierhoff; U Pfeifer
Journal:  J Hepatol       Date:  1996       Impact factor: 25.083

8.  Leptin is involved in gender-related differences in insulin sensitivity.

Authors:  J M Fernández-Real; R Casamitjana; W Ricart-Engel
Journal:  Clin Endocrinol (Oxf)       Date:  1998-10       Impact factor: 3.478

9.  Positional cloning of the mouse obese gene and its human homologue.

Authors:  Y Zhang; R Proenca; M Maffei; M Barone; L Leopold; J M Friedman
Journal:  Nature       Date:  1994-12-01       Impact factor: 49.962

10.  Leptin receptor action in hepatic cells.

Authors:  Y Wang; K K Kuropatwinski; D W White; T S Hawley; R G Hawley; L A Tartaglia; H Baumann
Journal:  J Biol Chem       Date:  1997-06-27       Impact factor: 5.157

View more
  7 in total

Review 1.  Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies.

Authors:  Jing-Ting Li; Zhang-Xiu Liao; Jie Ping; Dan Xu; Hui Wang
Journal:  J Gastroenterol       Date:  2008-07-04       Impact factor: 7.527

2.  Pathology of the liver in obese and diabetic ob/ob and db/db mice fed a standard or high-calorie diet.

Authors:  Viviane Trak-Smayra; Valérie Paradis; Julie Massart; Selim Nasser; Victor Jebara; Bernard Fromenty
Journal:  Int J Exp Pathol       Date:  2011-11-25       Impact factor: 1.925

3.  Adiponectin as an anti-fibrotic and anti-inflammatory adipokine in the liver.

Authors:  Pil-Hoon Park; Carlos Sanz-Garcia; Laura E Nagy
Journal:  Curr Pathobiol Rep       Date:  2015-09-30

4.  FGF21 ameliorates hepatic fibrosis by multiple mechanisms.

Authors:  Fanrui Meng; Mir Hassan Khoso; Kai Kang; Qi He; Yukai Cao; Xinghao Jiang; Wei Xiao; Deshan Li
Journal:  Mol Biol Rep       Date:  2021-09-18       Impact factor: 2.316

5.  An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective study.

Authors:  Spilios Manolakopoulos; Sotirios Bethanis; Charis Liapi; Fotini Stripeli; Pantelis Sklavos; Alexandra Margeli; Aggeliki Christidou; Aggeliki Katsanika; Evangellos Vogiatzakis; Dimitrios Tzourmakliotis; Stamatios Theocharis
Journal:  BMC Gastroenterol       Date:  2007-05-31       Impact factor: 3.067

Review 6.  The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies.

Authors:  Jun Xu; Xiao Liu; Yukinori Koyama; Ping Wang; Tian Lan; In-Gyu Kim; In H Kim; Hsiao-Yen Ma; Tatiana Kisseleva
Journal:  Front Pharmacol       Date:  2014-07-22       Impact factor: 5.810

Review 7.  Nonalcoholic fatty liver disease: Diagnostic biomarkers.

Authors:  Fatemeh Hadizadeh; Elham Faghihimani; Peyman Adibi
Journal:  World J Gastrointest Pathophysiol       Date:  2017-05-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.